Tulane University Health Sciences Center

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Tulane University Health Sciences Center sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 10 completed top decile by trial count

Tulane University Health Sciences Center: 10 sponsored US clinical trials, none currently recruiting.

Tulane University Health Sciences Center sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 4 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Malaria, with 1 trials.

Top-decile sponsor footprint

Tulane University Health Sciences Center ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 4

Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)

NCT02237079
COMPLETED Phase 3

Trichomonas Vaginalis Repeat Infections Among HIV Negative Women

NCT01832480
COMPLETED

DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women

NCT01874158
COMPLETED NA

e-SiHLE: An Internet Pregnancy Prevention for Older Teenage Girls

NCT01579617
COMPLETED NA

Study of Macronutrients and Heart Disease Risk

NCT00609271
COMPLETED Phase 4

Trichomonas Vaginalis Recurrence Among HIV+ Women

NCT01018095
COMPLETED Phase 1

Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial

NCT00455494
COMPLETED Phase 4

Comparison of Insulins Aspart and Lispro in Insulin Pumps

NCT00461331
COMPLETED Phase 2

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

NCT00028860
COMPLETED Phase 1

Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine

NCT00323375

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 1
Phase 4 3

Therapeutic Areas

Malaria 1

How the Tulane University Health Sciences Center archive is shaped

10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).

Phase mix: 4 late (III/IV) vs 3 early (I/II) (balanced across stages).

Top condition: Malaria (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Tulane University Health Sciences Center: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Tulane University Health Sciences Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Tulane University Health Sciences CenterAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Tulane University Health Sciences Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Tulane University Health Sciences Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Tulane University Health Sciences Center page

10 registered trials is a research-attention snapshot, not an endorsement of Tulane University Health Sciences Center or any single study.

  • None of Tulane University Health Sciences Center's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Malaria is the condition Tulane University Health Sciences Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Malaria trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Tulane University Health Sciences Center pipeline card: 10 registered trials from official public datasets.Report a data error.